Höchsmann B - Search Results

1

DNA methylation in PRDM8 is indicative for dyskeratosis congenita.

Weidner CI, Lin Q, Birkhofer C, Gerstenmaier U, Kaifie A, Kirschner M, Bruns H, Balabanov S, Trummer A, Stockklausner C, Höchsmann B, Schrezenmeier H, Wlodarski M, Panse J, Brümmendorf TH, Beier F, Wagner W. Weidner CI, et al. Among authors: hochsmann b. Oncotarget. 2016 Mar 8;7(10):10765-72. doi: 10.18632/oncotarget.7458. Oncotarget. 2016. PMID: 26909595 Free PMC article.

2

Hemispheric stroke does not mobilize cd34+ hematopoietic stem cells into the peripheral blood.

Höchsmann B, Huber R, Schauwecker P, Schrezenmeier H, Wiesneth M, Storch A. Höchsmann B, et al. Neurology. 2009 Apr 7;72(14):1277-8. doi: 10.1212/01.wnl.0000345669.99690.e9. Neurology. 2009. PMID: 19349609 No abstract available.

3

Eculizumab opens a new era of treatment for paroxysmal nocturnal hemoglobinuria.

Schrezenmeier H, Höchsmann B. Schrezenmeier H, et al. Among authors: hochsmann b. Expert Rev Hematol. 2009 Feb;2(1):7-16. doi: 10.1586/17474086.2.1.7. Expert Rev Hematol. 2009. PMID: 21082989 Review.

4

Paroxysmal nocturnal hemoglobinuria (PNH): higher sensitivity and validity in diagnosis and serial monitoring by flow cytometric analysis of reticulocytes.

Höchsmann B, Rojewski M, Schrezenmeier H. Höchsmann B, et al. Ann Hematol. 2011 Aug;90(8):887-99. doi: 10.1007/s00277-011-1177-4. Epub 2011 Feb 26. Ann Hematol. 2011. PMID: 21359652 Free PMC article.

5

Paroxysmal nocturnal haemoglobinuria treatment with eculizumab is associated with a positive direct antiglobulin test.

Höchsmann B, Leichtle R, von Zabern I, Kaiser S, Flegel WA, Schrezenmeier H. Höchsmann B, et al. Vox Sang. 2012 Feb;102(2):159-66. doi: 10.1111/j.1423-0410.2011.01530.x. Epub 2011 Sep 19. Vox Sang. 2012. PMID: 21929681 Free PMC article.

6

Drugs that inhibit complement.

Schrezenmeier H, Höchsmann B. Schrezenmeier H, et al. Among authors: hochsmann b. Transfus Apher Sci. 2012 Feb;46(1):87-92. doi: 10.1016/j.transci.2011.11.012. Epub 2011 Dec 13. Transfus Apher Sci. 2012. PMID: 22169380 Review.

7

Supportive care in severe and very severe aplastic anemia.

Höchsmann B, Moicean A, Risitano A, Ljungman P, Schrezenmeier H. Höchsmann B, et al. Bone Marrow Transplant. 2013 Feb;48(2):168-73. doi: 10.1038/bmt.2012.220. Epub 2012 Dec 3. Bone Marrow Transplant. 2013. PMID: 23208312 Review.

8

Targeted therapy with eculizumab for inherited CD59 deficiency.

Höchsmann B, Dohna-Schwake C, Kyrieleis HA, Pannicke U, Schrezenmeier H. Höchsmann B, et al. N Engl J Med. 2014 Jan 2;370(1):90-2. doi: 10.1056/NEJMc1308104. N Engl J Med. 2014. PMID: 24382084 No abstract available.

9

A new blood group antigen is defined by anti-CD59, detected in a CD59-deficient patient.

Anliker M, von Zabern I, Höchsmann B, Kyrieleis H, Dohna-Schwake C, Flegel WA, Schrezenmeier H, Weinstock C. Anliker M, et al. Among authors: hochsmann b. Transfusion. 2014 Jul;54(7):1817-22. doi: 10.1111/trf.12531. Epub 2014 Jan 3. Transfusion. 2014. PMID: 24383981 Free PMC article.

10

Successful use of eculizumab for treatment of an acute hemolytic reaction after ABO-incompatible red blood cell transfusion.

Weinstock C, Möhle R, Dorn C, Weisel K, Höchsmann B, Schrezenmeier H, Kanz L. Weinstock C, et al. Among authors: hochsmann b. Transfusion. 2015 Mar;55(3):605-10. doi: 10.1111/trf.12882. Epub 2014 Sep 23. Transfusion. 2015. PMID: 25251967

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

58 results

Search Page